Appeals court lifts halt on generic Entresto launch: report
Entresto was the company's top-selling product in 2023, generating sales of around $6B. MSN had been aiming to launch its ...
pharmaphorum1d
Judge rebuffs Novartis bid to block generic Entresto
A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto. MSN Pharma was given FDA approval for its ...
Novartis loses appeal to block generic Entresto launch: report
MSN’s generic version of Entresto, Novartis’s best-selling product, was approved by the FDA in July.Novartis has been suing ...
pharmaphorum2d
Novartis bid to block generic Entresto in US suffers setback
A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...
Fierce Pharma14d
Novartis plans 427 layoffs as looming Entresto patent cliff sparks marketing refresh
Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...